Soy Isoflavones and Cancer Prevention

References

• Kelloff G.J., Boone C.W., Steele V.E., Fay J.R., Lubet R.A., Crowell J.A., Sigman C.C. Mechanistic considerations in chemopreventive drug development. J. Cell Biochem. Suppl. 1994; 20: 1–24
   PubMedGoogle Scholar
• Adlercreutz C.H., Goldin B.R., Gorbach S.L., Hockerstedt K.A., Watanabe S., Hamalainen E.K., Markkanen M.H., Makela T.H., Wahala K.T., Adlercreutz T. Soybean phytoestrogen intake and cancer risk. J. Nutr. 1995; 125(3 Suppl.)757S–770S
   PubMed Web of Science ®Google Scholar
• Hebert J.R., Hurley T.G., Olendzki B.C., Teas J., Ma Y., Hampl J.S. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. Cancer Inst. 1998; 90(21)1637–1647
   PubMed Web of Science ®Google Scholar
• Adlercreutz H., Honjo H., Higashi A., Fotsis T., Hamalainen E., Hasegawa T., Okada H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 1991; 54(6)1093–1100
   PubMed Web of Science ®Google Scholar
• Lee H.P., Gourley L., Duffy S.W., Esteve J., Lee J., Day N.E. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337(8751)1197–1200
   PubMed Web of Science ®Google Scholar
• Jacobsen B.K., Knutsen S.F., Fraser G.E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9(6)553–557
   PubMed Web of Science ®Google Scholar
• Adlercreutz H., Markkanen H., Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342(8881)1209–1210
   PubMed Web of Science ®Google Scholar
• Mills P.K., Beeson W.L., Phillips R.L., Fraser G.E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64(3)598–604
   PubMed Web of Science ®Google Scholar
• Kumar N.B., Cantor A., Allen K., Riccardi D., Cox C.E. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002; 94: 1166–1174
   PubMed Web of Science ®Google Scholar
• Li Y., Upadhyay S., Bhuiyan M., Sarkar F.H. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999; 18(20)3166–3172
   PubMed Web of Science ®Google Scholar
• Li Y., Bhuiyan M., Sarkar F.H. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int. J. Oncol. 1999; 15(3)525–533
   PubMed Web of Science ®Google Scholar
• Lian F., Bhuiyan M., Li Y.W., Wall N., Kraut M., Sarkar F.H. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer 1998; 31(3)184–191
   PubMed Web of Science ®Google Scholar
• Alhasan S.A., Pietrasczkiwicz H., Alonso M.D., Ensley J., Sarkar F.H. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr. Cancer 1999; 34(1)12–19
   PubMed Web of Science ®Google Scholar
• Upadhyay S., Neburi M., Chinni S.R., Alhasan S., Miller F., Sarkar F.H. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin. Cancer Res. 2001; 7(6)1782–1789
   PubMed Web of Science ®Google Scholar
• Spinozzi F., Pagliacci M.C., Migliorati G., Moraca R., Grignani F., Riccardi C., Nicoletti I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 1994; 18(6)431–439
   PubMed Web of Science ®Google Scholar
• Constantinou A., Huberman E. Genistein as an inducer of tumor cell differentiation: possible mechanisms of action. Proc. Soc. Exp. Biol. Med. 1995; 208(1)109–115
   PubMed Web of Science ®Google Scholar
• Davis J.N., Singh B., Bhuiyan M., Sarkar F.H. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer 1998; 32(3)123–131
   PubMed Web of Science ®Google Scholar
• Messina M.J. J. Legumes and soybeans: overview of their nutritional profiles and health effects. Am. J. Clin. Nutr. 1999; 70(3 Suppl.)439S–450S
   PubMed Web of Science ®Google Scholar
• Knight D.C., Eden J.A. A review of the clinical effects of phytoestrogens. Obstet. Gynecol. 1996; 2(5 Pt 2)897–904
   Google Scholar
• Zava D.T., Dollbaum C.M., Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc. Soc. Exp. Biol. Med. 1998; 217(3)369–378
   PubMed Web of Science ®Google Scholar
• Martin P.M., Horwitz K.B., Ryan D.S., McGuire W.L. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 1978; 103(5)1860–1867
   PubMed Web of Science ®Google Scholar
• Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der B.B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139(10)4252–4263
   PubMed Web of Science ®Google Scholar
• Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987; 262(12)5592–5595
   PubMed Web of Science ®Google Scholar
• Hunter T. A thousand and one protein kinases. Cell 1987; 50(6)823–829
   PubMed Web of Science ®Google Scholar
• Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61(2)203–212
   PubMed Web of Science ®Google Scholar
• Okura A., Arakawa H., Oka H., Yoshinari T., Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12] Ha-ras-transformed NIH 3T3 cells. Biochem. Biophys. Res. Commun. 1988; 157(1)183–189
   PubMed Web of Science ®Google Scholar
• Evans B.A., Griffiths K., Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J. Endocrinol. 1995; 147(2)295–302
   PubMed Web of Science ®Google Scholar
• Huang J., Nasr M., Kim Y., Matthews H.R. Genistein inhibits protein histidine kinase. J. Biol. Chem. 1992; 267(22)15511–15515
   PubMed Web of Science ®Google Scholar
• Ruiz-Larrea M.B., Mohan A.R., Paganga G., Miller N.J., Bolwell G.P., Rice-Evans C.A. Antioxidant activity of phytoestrogenic isoflavones. Free Radic. Res. 1997; 26(1)63–70
   PubMed Web of Science ®Google Scholar
• Zhou Y., Lee A.S. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J. Natl. Cancer Inst. 1998; 90(5)381–388
   PubMed Web of Science ®Google Scholar
• Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., FitzGerald M.J., Rothstein T.L., Sherr D.H., Sonenshein G.E. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 1996; 15(17)4682–4690
   PubMed Web of Science ®Google Scholar
• Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274(5288)787–789
   PubMed Web of Science ®Google Scholar
• Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282(5392)1318–1321
   PubMed Web of Science ®Google Scholar
• Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96(6)857–868
   PubMed Web of Science ®Google Scholar
• Sharma O.P., Adlercreutz H., Strandberg J.D., Zirkin B.R., Coffey D.S., Ewing L.L. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J. Steroid Biochem. Mol. Biol. 1992; 43(6)557–564
   PubMed Web of Science ®Google Scholar
• Onozawa M., Kawamori T., Baba M., Fukuda K., Toda T., Sato H., Ohtani M., Akaza H., Sugimura T., Wakabayashi K. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J. Cancer Res. 1999; 90(4)393–398
   PubMedGoogle Scholar
• Landstrom M., Zhang J.X., Hallmans G., Aman P., Bergh A., Damber J.E., Mazur W., Wahala K., Adlercreutz H. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 1998; 36(3)151–161
   PubMed Web of Science ®Google Scholar
• Zhou J.R., Gugger E.T., Tanaka T., Guo Y., Blackburn G.L., Clinton S.K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 1999; 129(9)1628–1635
   PubMed Web of Science ®Google Scholar
• Lamartiniere C.A., Moore J.B., Brown N.M., Thompson R., Hardin M.J., Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995; 16(11)2833–2840
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Evans W.E., Forsyth C.J., Waddick K.G., Ahlgren L.T., Chelstrom L.M., Burkhardt A., Bolen J., Myers D.E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995; 267(5199)886–891
   PubMed Web of Science ®Google Scholar
• Barnes S., Peterson T.G. Biochemical targets of the isoflavone genistein in tumor cell lines. Proc. Soc. Exp. Biol. Med. 1995; 208(1)103–108
   PubMed Web of Science ®Google Scholar
• Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 1995; 125(3 Suppl.)777S–783S
   PubMed Web of Science ®Google Scholar
• Matsukawa Y., Marui N., Sakai T., Satomi Y., Yoshida M., Matsumoto K., Nishino H., Aoike A. Genistein arrests cell cycle progression at G2-M. Cancer Res. 1993; 53(6)1328–1331
   PubMed Web of Science ®Google Scholar
• Casagrande F., Darbon J.M. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp. Cell Res. 2000; 258(1)101–108
   PubMed Web of Science ®Google Scholar
• Pagliacci M.C., Smacchia M., Migliorati G., Grignani F., Riccardi C., Nicoletti I. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur. J. Cancer 1994; 30A(11)1675–1682
   PubMed Web of Science ®Google Scholar
• Kuzumaki T., Kobayashi T., Ishikawa K. Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun. 1998; 251(1)291–295
   PubMed Web of Science ®Google Scholar
• Lian F., Li Y., Bhuiyan M., Sarkar F.H. p53-Independent apoptosis induced by genistein in lung cancer cells. Nutr. Cancer 1999; 33(2)125–131
   PubMed Web of Science ®Google Scholar
• Alhasan S.A., Ensley J.F., Sarkar F.H. Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int. J. Oncol. 2000; 16(2)333–338
   PubMed Web of Science ®Google Scholar
• Chiarugi V., Magnelli L., Cinelli M., Basi G. Apoptosis and the cell cycle. Cell Mol. Biol. Res. 1994; 40(7–8)603–612
   PubMedGoogle Scholar
• Huang P., Ballal K., Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res. 1997; 57(16)3407–3414
   PubMed Web of Science ®Google Scholar
• Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78(4)539–542
   PubMed Web of Science ®Google Scholar
• Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371(6495)346–347
   PubMed Web of Science ®Google Scholar
• Tewari M., Quan L.T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D.R., Poirier G.G., Salvesen G.S., Dixit V.M. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81(5)801–809
   PubMed Web of Science ®Google Scholar
• Darmon A.J., Nicholson D.W., Bleackley R.C. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377(6548)446–448
   PubMed Web of Science ®Google Scholar
• Philpott N.J., Turner A.J., Scopes J., Westby M., Marsh J.C., Gordon-Smith E.C., Dalgleish A.G., Gibson F.M. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87(6)2244–2251
   PubMed Web of Science ®Google Scholar
• Kyle E., Neckers L., Takimoto C., Curt G., Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol. Pharmacol. 1997; 51(2)193–200
   PubMed Web of Science ®Google Scholar
• Park J.R., Hockenbery D.M. BCL-2, a novel regulator of apoptosis. J. Cell Biochem. 1996; 60(1)12–17
   PubMed Web of Science ®Google Scholar
• Findley H.W., Gu L., Yeager A.M., Zhou M. Expression and regulation of Bcl-2 Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997; 89(8)2986–2993
   PubMed Web of Science ®Google Scholar
• Kane D.J., Sarafian T.A., Anton R., Hahn H., Gralla E.B., Valentine J.S., Ord T., Bredesen D.E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262(5137)1274–1277
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Kinzler K.W. p53 Function and dysfunction. Cell 1992; 70(4)523–526
   PubMed Web of Science ®Google Scholar
• el Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75(4)817–825
   PubMed Web of Science ®Google Scholar
• Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75(4)805–816
   PubMed Web of Science ®Google Scholar
• Agarwal M.L., Agarwal A., Taylor W.R., Stark G.R. p53 Controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1995; 92(18)8493–8497
   PubMed Web of Science ®Google Scholar
• Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 Is a universal inhibitor of cyclin kinases. Nature 1993; 366(6456)701–704
   PubMed Web of Science ®Google Scholar
• Shao Z.M., Alpaugh M.L., Fontana J.A., Barsky S.H. Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J. Cell Biochem. 1998; 69(1)44–54
   PubMed Web of Science ®Google Scholar
• Wang T.T., Sathyamoorthy N., Phang J.M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996; 17(2)271–275
   PubMed Web of Science ®Google Scholar
• Wang C., Kurzer M.S. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr. Cancer 1997; 28(3)236–247
   PubMed Web of Science ®Google Scholar
• Verma I.M., Stevenson J.K., Schwarz E.M., Van Antwerp D., Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 1995; 9(22)2723–2735
   PubMed Web of Science ®Google Scholar
• Thanos D., Maniatis T. NF-kappa B.: a lesson in family values. Cell 1995; 80(4)529–532
   PubMed Web of Science ®Google Scholar
• Ghosh G., van Duyne G., Ghosh S., Sigler P.B. Structure of NF-kappa B p50 homodimer bound to a kappa B site. Nature 1995; 373(6512)303–310
   PubMed Web of Science ®Google Scholar
• Muller C.W., Rey F.A., Sodeoka M., Verdine G.L., Harrison S.C. Structure of the NF-kappa B p50 homodimer bound to DNA. Nature 1995; 373(6512)311–317
   PubMed Web of Science ®Google Scholar
• Chen Z.J., Parent L., Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 1996; 84(6)853–862
   PubMed Web of Science ®Google Scholar
• Chen Z., Hagler J., Palombella V.J., Melandri F., Scherer D., Ballard D., Maniatis T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 1995; 9(13)1586–1597
   PubMed Web of Science ®Google Scholar
• Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 1995; 14(12)2876–2883
   PubMed Web of Science ®Google Scholar
• Pahl H.L., Baeuerle P.A. Control of gene expression by proteolysis. Curr. Opin. Cell Biol. 1996; 8(3)340–347
   PubMed Web of Science ®Google Scholar
• Lenardo M.J., Baltimore D. NF-kappa B.: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58(2)227–229
   PubMed Web of Science ®Google Scholar
• Baldwin A.S., Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996; 14: 649–683
   PubMed Web of Science ®Google Scholar
• Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274(5288)782–784
   PubMed Web of Science ®Google Scholar
• Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S., Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383)1680–1683
   PubMed Web of Science ®Google Scholar
• Beg A.A., Sha W.C., Bronson R.T., Ghosh S., Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995; 376(6536)167–170
   PubMed Web of Science ®Google Scholar
• Davis J.N., Kucuk O., Sarkar F.H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr. Cancer 1999; 35(2)167–174
   PubMed Web of Science ®Google Scholar
• Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995; 267(5203)1485–1488
   PubMed Web of Science ®Google Scholar
• Zandi E., Chen Y., Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 1998; 281(5381)1360–1363
   PubMed Web of Science ®Google Scholar
• Karin M., Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin. Immunol. 2000; 12(1)85–98
   PubMed Web of Science ®Google Scholar
• Lee F.S., Peters R.T., Dang L.C., Maniatis T. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc. Natl. Acad. Sci. U.S.A. 1998; 95(16)9319–9324
   PubMed Web of Science ®Google Scholar
• Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H., Okumura K. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc. Natl. Acad. Sci. U.S.A. 1998; 95(7)3537–3542
   PubMed Web of Science ®Google Scholar
• Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88(4)435–437
   PubMed Web of Science ®Google Scholar
• Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376(6541)599–602
   PubMed Web of Science ®Google Scholar
• Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81(5)727–736
   PubMed Web of Science ®Google Scholar
• Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996; 15(23)6541–6551
   PubMed Web of Science ®Google Scholar
• Rommel C., Clarke B.A., Zimmermann S., Nunez L., Rossman R., Reid K., Moelling K., Yancopoulos G.D., Glass D.J. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286(5445)1738–1741
   PubMed Web of Science ®Google Scholar
• Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401(6748)86–90
   PubMed Web of Science ®Google Scholar
• Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401(6748)82–85
   PubMed Web of Science ®Google Scholar
• Li Y., Sarkar F.H. Inhibition of NF-kB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 2002; 8(7)2369–2317
   PubMed Web of Science ®Google Scholar
• Montgomery J.S., Price D.K., Figg W.D. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol. 2001; 195(2)138–146
   PubMed Web of Science ®Google Scholar
• Kupelian P., Katcher J., Levin H., Zippe C., Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48(2)249–260
   PubMed Web of Science ®Google Scholar
• Sato N., Gleave M.E., Bruchovsky N., Rennie P.S., Goldenberg S.L., Lange P.H., Sullivan L.D. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J. Steroid Biochem. Mol. Biol. 1996; 58(2)139–146
   PubMed Web of Science ®Google Scholar
• Luke M.C., Coffey D.S. Human androgen receptor binding to the androgen response element of prostate specific antigen. J. Androl. 1994; 15(1)41–51
   PubMed Web of Science ®Google Scholar
• Davis J.N., Muqim N., Bhuiyan M., Kucuk O., Pienta K.J., Sarkar F.H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int. J. Oncol. 2000; 16(6)1091–1097
   PubMed Web of Science ®Google Scholar
• Davis J.N., Kucuk O., Sarkar H.F. Expression of prostate specific antigen (PSA) is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog. 2002, (in press)
   Web of Science ®Google Scholar
• Fritz W.A., Wang J., Eltoum I.E., Lamartiniere C.A. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell Endocrinol. 2002; 186(1)89–99
   PubMed Web of Science ®Google Scholar
• Kumar R., Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin. Oncol. 2001; 28(5 Suppl. 16)27–32
   PubMed Web of Science ®Google Scholar
• Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19(53)6115–6121
   PubMed Web of Science ®Google Scholar
• Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., Muschel R.J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994; 14(1–6)246–258
   PubMedGoogle Scholar
• Saaristo A., Karpanen T., Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000; 19(53)6122–6129
   PubMed Web of Science ®Google Scholar
• Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997; 72(1)1–22
   PubMed Web of Science ®Google Scholar
• Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur. J. Cancer 1995; 31A(7–8)1101–1104
   PubMed Web of Science ®Google Scholar
• Fotsis T., Pepper M., Adlercreutz H., Hase T., Montesano R., Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr. 1995; 125(3 Suppl.)790S–797S
   PubMed Web of Science ®Google Scholar
• Li D., Yee J.A., McGuire M.H., Murphy P.A., Yan L. Soybean isoflavones reduce experimental metastasis in mice. J. Nutr. 1999; 129(5)1075–1078
   PubMed Web of Science ®Google Scholar
• Tan M., Yao J., Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997; 57(6)1199–1205
   PubMed Web of Science ®Google Scholar
• Alhasan S.A., Aranha O., Sarkar F.H. Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin. Cancer Res. 2001; 7(12)4174–4181
   PubMed Web of Science ®Google Scholar
• Li, Y.; Sarkar, F.H. Gene expression profile of PC3 prostate cancer cells exposed to genistein revealed novel molecular pathways for therapeutic intervention. AACR 93rd Annual Meeting 2002, LB-141 (Proceedings Supplement), 81
   Google Scholar
• Wei H., Wei L., Frenkel K., Bowen R., Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr. Cancer 1993; 20(1)1–12
   PubMed Web of Science ®Google Scholar
• Kameoka S., Leavitt P., Chang C., Kuo S.M. Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett. 1999; 146(2)161–167
   PubMed Web of Science ®Google Scholar
• Toledano M.B., Leonard W.J. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. U.S.A. 1991; 88(10)4328–4332
   PubMed Web of Science ®Google Scholar
• Dudek E.J., Shang F., Taylor A. H(2)O(2)-mediated oxidative stress activates NF-kappa B in lens epithelial cells. Free Radic. Biol. Med. 2001; 31(5)651–658
   PubMed Web of Science ®Google Scholar
• Davis J.N., Kucuk O., Djuric Z., Sarkar F.H. Soy isoflavone supplementation in healthy men prevents NF-kappaB activation by TNF-alpha in blood lymphocytes. Free Radic. Biol. Med. 2001; 30(11)1293–1302
   PubMed Web of Science ®Google Scholar